Lupus Australia Briefing

• Efficacy highlights: 50% of lupus nephritis patients reached complete renal response and 54% hit DORIS remission at 12 months, with all stopping...

A first genome-wide association study reveals concordant immune associations spanning systemic lupus, type 1 diabetes, rheumatoid arthritis and...

Evidence on telitacicept efficacy and safety in adults with SLE draws from placebo-controlled randomized trials, other comparative studies, and single-arm cohorts, shaping views on its potential place in future treatment options.

Arina's story reveals how lupus reshapes daily life even when symptoms stay hidden.

• Identity: She refuses to let SLE define her, keeping her...

Could assumptions about sex influence the care offered to women with lupus after diagnosis?

• A review of 38 studies found women less likely to...

Lunaire Lupus Tracker offers a private, offline diary for flares, symptoms and triggers, with PDF reports to share with clinicians.

Key...

Adicet Bio will report Phase 1 clinical data on prula-cel (formerly ADI-001) for systemic lupus erythematosus with or without lupus nephritis on...

No biologic is approved for skin-only cutaneous lupus, so use remains off-label.

• Anifrolumab leads evidence: From SLE trials with skin involvement;...

Immunovant discontinued development of IMVT-1402 for cutaneous lupus erythematosus after the drug failed to meet its primary endpoint in a proof-of-concept trial.

A major shift in SLE understanding now positions innate immune activation via the type I interferon axis as a central link between antiviral-like...

A Senegalese hospital study found SLE in just 84 patients over 2017-2024, giving a prevalence of 0.15%. Female predominance was marked (sex ratio...

Consistent hydroxychloroquine use significantly lowers heart disease risk for lupus patients, with non-adherent individuals facing higher risk within...

• Community support proves essential as warriors share frustrations with dismissive doctors, misdiagnoses and medication costs.
• The Walk to End...

Australia’s combination of manufacturing infrastructure and an efficient Phase I trials system positions it to speed mRNA therapies for diverse...

Chronic inflammation in lupus redirects neutrophils to produce weaker NETs against bacteria, explaining why overactive immunity fails to protect.

-...

Three circulating biomarker approaches show strong potential to support earlier lupus nephritis diagnosis and flare monitoring.

• Serum YB-1-2G...

EULAR now recommends low-dose aspirin for asymptomatic aPL carriers and SLE patients without prior thrombotic or obstetric APS events to reduce thrombosis and pregnancy risks.

First-degree relatives of lupus patients have a higher risk of developing lupus or other autoimmune diseases themselves. This points to elevated risk, not a certainty of disease onset.

Isoniazid can induce cutaneous lupus even without serologic markers, raising the risk of missed diagnoses during therapy. Clinicians must remain alert to this adverse effect to ensure timely recognition and management.

Studies in T cells from SLE patients and murine lupus models show the glycolytic inhibitor 2-DG alters cellular metabolism, providing mechanistic...